Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2229-2239

  Mariotti, Sabrina ^a   Teloni, Raffaela ^a   Von Hunolstein, Christina ^a   Romagnoli, Giulia ^a   Orefici, Graziella ^a   Nisini, Roberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antitoxin antibodies; CpG motifs; Glycoconjugate vaccines

Indexed keywords

BACTERIUM ANTIBODY; CROSS REACTING ANTIGEN; DIPHTHERIA TOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; POLYRIBOSYLRIBITOL PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIPHTHERIA; DRUG CONJUGATION; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA VACCINATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CERCOPITHECUS AETHIOPS; DIPHTHERIA TOXIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; NASAL MUCOSA; OLIGODEOXYRIBONUCLEOTIDES; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, CONJUGATE; VERO CELLS;

EID: 0037157240     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00113-5     Document Type: Article

References (46)

1. Impact of immunization on Haemophilus influenzae type b disease
2. Bacterial meningitis in the United States, 1978-1981: The National Bacterial Meningitis Surveillance Study
3. The epidemiology and prevention of diseases caused by Haemophilus influenzae type b
4. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland
5. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugated
6. Declining incidence of Haemophilus influenzae type b since introduction of vaccination
7. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy
8. Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests
9. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines
10. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines
11. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin-6, interleukin-12, and interferon-γ
12. Immune activation by bacterial DNA: A new genetic code
13. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
14. DNA from bacteria, but not from vertebrates induces interferons, activates natural killer cells and inhibits tumor growth
15. CpG motifs as immune adjuvants
16. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
17. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
18. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
19. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
20. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
21. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
22. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
23. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type-1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine
24. CpG oligodeoxynucleotides act as adjuvants that switch on T helper-1 (Th1) immunity
25. DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen
26. Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations
27. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
28. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
29. CpG DNA as mucosal adjuvant
30. Cholera toxin and related enterotoxins as potent immune modulators
31. E. coli heat-labile enterotoxin following intranasal oral and intravaginal immunization
32. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
33. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
34. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
35. Immunostimulatory DNA is a potent mucosal adjuvant
36. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant
37. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
38. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo
39. Lymphokine control of in vivo immunoglobulin isotype selection
40. Monoclonal antibodies as probes of tetanus toxin structure and function
41. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosyl ribitol phosphate (PRP) conjugated vaccines in the mouse model
42. Neutralization of diphtheria toxin by human immunoglobulin classes and subunits
43. Evaluation of toxin neutralisation in test systems for diphtheria antibody assessment
44. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: A follow-up of two different regimens of infant vaccination
45. 197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs
46. 197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery